References
- Mintun MA, Lo AC, Evans C, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691–1704.
- Alzheimer’s facts and figures [ cited 2021 April 14] Available from: https://www.alz.org/alzheimers-dementia/facts-figures
- Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179:312–339.
- Leinenga G, Koh WK, Götz J. A comparative study of the effects of aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 model of Alzheimer disease. Alzheimer’s Res Ther. 2021;13(1):76.
- Salloway S, Honigberg LA, Cho W, et al. Amyloid positron emission tomography and cerebral fluid results from a crenezumab ant-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE). Alzheimer’s Res Ther. 2018;10:97.
- DeMattos RB, Lu J, Tang Y, et al. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer’s disease mice. Neuron. 2012;76(5):908–920.
- Fleisher AS, Lowe SL, Liu P, et al. Significant and sustained florbetapir F18 uptake reduction in patients with symptomatic Alzheimer’s disease with LY3002813, a β-amyloid plaque-specific antibody. Alzheimers Dement. 2018;14(7S_Part_4):239–40.
- Lowe SL, Willis BA, Hawdon A, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer’s disease. Alzheimer’s Dement. 2021;7:e12112.
- Panza F, Lozupone M, Logroscrino G, et al. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019;15:73–88.
- Cummings J, Froelich L, Black SE, et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm2) in Alzheimer’s disease. Dement Geriatri Cogn Disord. 2012;33(5):341–353.
- Devous SMD, Fleisher AS, Pontecorvo M, et al. Relationships between cognition and neuropathological tau in Alzheimer’s disease assessed by 18F flortuacipir PET. J Alzheimers Dis. 2021;80(3):1091–1104.
- Panza F, Lozupone M, Belloma A, et al. Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer’s disease patients. Ageing Res Rev. 2019;55:100948.
- ClinicalTrials.gov. A follow-on study of donanemab (LY3002813) with video assessments in participants with Alzheimer’s disease (TRAILBLAZER-EXT). https://clinicaltrials.gov/ct2/show/NCT04640077?term=DONANEMAB&draw=2&rank=2 [cited 2021 April 23]
- ClinicalTrials.gov. A study of donanemab (LY3002813) in participants with early Alzheimer’s disease (TRAILBLAZER-ALZ 2). https://clinicaltrials.gov/ct2/show/NCT04437511?term=DONANEMAB&draw=2&rank=1#studydesc [cited 2021 April 23]
- Lozupone M, Solfrizzi V, D’Urso F, et al. Anti-amyloid-β agents for the treatment of Alzheimer’s disease: an update on emerging drugs. Expert Opin Emerg Drugs. 2020;25(3):319–335.
- Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med. 2018;378(4):321–330.
- ClinicalTrials.gov. Clinical trial of solanezumab for older individuals who may be at risk of memory loss (A4). https://clinicaltrials.gov/ct2/show/NCT02008357?term=solanezumab&draw=2&rank=5. [cited 2021 April 26]
- ClinicalTrials.gov. A study of gantenerumab in participants with prodromal Alzheimer’s disease. https://clinicaltrials.gov/ct2/show/NCT01224106?term=nct01224106&draw=2&rank=1. [cited 2021 June 14]
- ClinicalTrials.gov. A study of gantenerumab in participants with mild Alzheimer Disease. https://clinicaltrials.gov/ct2/show/NCT02051608?term=nct02051608&draw=2&rank=1. [cited 2021 June 14]
- Klein G, Delmar P, Voyle N, et al. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis. Alzheimer’s Res Ther. 2019;11(1):101.
- Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer’s Res Ther. 2021;13(1):80.
- ClinicalTrials.gov. A study to confirm safety and efficacy of lecanemab in participants with early Alzheimer’s disease (Clarity AD). https://clinicaltrials.gov/ct2/show/NCT03887455?term=lecanemab&draw=2&rank=2. [cited 2021 April 26]
- ClinicalTrials.gov. AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer’s Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid. https://clinicaltrials.gov/ct2/show/NCT04468659?term=lecanemab&draw=2&rank=1. [cited 2021 April 26]
- 221AD301 Phase 3 study of aducanumab (BIIB037) in early Alzheimer’s disease (ENGAGE) https://clinicaltrials.gov/ct2/show/NCT02477800?term=ADUCANUMAB&draw=2&rank=7 [ cited 2021 June 6]
- 221AD302 Phase 3 study of aducanumab (BIIB037) in early Alzheimer’s disease (EMERGE) https://clinicaltrials.gov/ct2/show/NCT02484547?term=ADUCANUMAB&draw=2&rank=6 [ cited 2021 June 6]
- EMERGE and ENGAGE topline results . Two phase 3 studies to evaluate aducanumab in patients with early Alzheimer’s disease. https://investors.biogen.com/static-files/8e58afa4-ba37-4250-9a78-2ecfb63b1dcb [ cited 2021 June 6]
- Cummings J, Aisen P, Lemere C, et al. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res Ther. 2021;13(1):1.
- Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement. 2021;17(4):696–701.
- Alexander GC, Emerson S, Kessekheim AS. Evaluation of aducanumab for Alzheimer disease. Scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA. 2021;325(17):1717.
- FDA grants accelerated approval for Alzheimer’s drug. [ cited 2021 June 6]. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug
- Doggrell SA. Grasping at straws: the failure of solanezumab to modify mild Alzheimer’s disease. Expert Opin Biol Ther. 2018;18(12):1189–1192.